Jiawei Danggui Beimu Kushen pills were shown to be effective in treating prostate cancer, improving patients' quality of life and potentially regulating serum PSA levels.
In this study, 234 patients suffering from prostate cancer were randomly assigned into two groups: an observation group and a control group, with 117 patients in each. The control group were administered oral bicalutamide tablets, while the observation group received Jiawei Danggui Beimu Kushen pills in addition to the control group's treatment. Numerous factors such as the treatment effectiveness, scores related to symptoms, immune function and quality of life were compared before and after the treatment. The levels of serum PSA and f-PSA in the patients were also monitored and compared at different intervals during the treatment.
After the treatment, the observation group showed a higher effective rate than the control group. The scores related to symptoms were reduced in both groups post treatment, but more so in the observation group. The quality-of-life scores increased in both groups but were particularly higher in the observation group. The levels of serum PSA and f-PSA were noted to decrease as the treatment time increased and were significantly lower in the observation group after 180 days of treatment. The observation group also showed a higher five-year cumulative survival rate. There was no significant difference in the occurrence of dizziness, fatigue, and gastrointestinal reactions; however, rates of dysuria and hematuria were found to be significantly less in the observation group. The pills were effective in reducing IPSS score and TCM syndrome scores, alleviating pain, and enhancing the quality of life.
